Skip to Content

BOOTS BLOCKED NOSE RELIEF 12MG CAPSULES

Active substance(s): PHENYLEPHRINE HYDROCHLORIDE / PHENYLEPHRINE HYDROCHLORIDE / PHENYLEPHRINE HYDROCHLORIDE

View full screen / Print PDF » Download PDF ⇩

PDF Transcript

SUMMARY OF PRODUCT CHARACTERISTICS

1.

NAME OF THE MEDICINAL PRODUCT
Boots Blocked Nose Relief 12mg Capsules

2

3

QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient

mg/cap

Phenylephrine Hydrochloride

12.00

PHARMACEUTICAL FORM
Capsule, hard (capsule)

4

CLINICAL PARTICULARS

4.1

Therapeutic indications
For the relief of nasal congestion associated with colds and hayfever.

4.2

Posology and method of administration
Adults and children over 12 years: One capsule if necessary, up to four times daily.
Children under 12 years: Not recommended.
Elderly: There is no need for dosage reduction in the elderly.

4.3

Contraindications
Hypersensitivity to any of the ingredients. Avoid in patients with cardiovascular
disease, high blood pressure, diabetes mellitus, closed angle glaucoma,
hyperthyroidism, prostatic enlargement and phaeochromocytoma. Patients being

treated with monamine oxidase inhibitors or within 14 days of ceasing such treatment
(see section 4.5).

4.4

Special warnings and precautions for use
This medicine should be used with caution in patients with occlusive vascular disease
including Raynaud’s Phenomenon.
Do not take for longer than 7 days, unless your doctor agrees.
If symptoms do not go away talk to your doctor.
Keep all medicines out of the reach of children.
Warning: Do not exceed the stated dose.
Patients with rare hereditary problems of galactose intolerance, Lapp lactase
deficiency of glucose-galactose malabsorbtion should not take this medicine.

4.5

Interaction with other medicinal products and other forms of interaction
Should not be given to patients being treated with monoamine oxidase inhibitors or
within 14 days of stopping such treatment. May enhance the effects of anticholinergic
drugs such as tricyclic antidepressants. May increase the possibility of arrhythmias in
digitalised patients. May enhance the cardiovascular effects of other
sympathomimetic amines (e.g. decongestants).
This medicine should not be taken together with vasodilators, Beta-blockers or
enzyme inducers such as alcohol.

4.6

Pregnancy and lactation
The safety of this medicine during pregnancy and lactation has not been established
but in view of a possible association of foetal abnormalities with first trimester
exposure to phenylephrine, the use of the product during pregnancy should be
avoided. In addition, because phenylephrine may reduce placental perfusion, the
product should not be used in patients with a history of pre-eclampsia. In view of the
lack of data on the use of phenylephrine during lactation, this medicine should not be
used during breast feeding.

4.7

Effects on ability to drive and use machines
No adverse effects known.

4.8

Undesirable effects
Adverse effects may include tachycardia, cardiac arrhythmias, palpitations,
hypertension, nausea, vomiting, headache and occasionally urinary retention in
males.
Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal
product is important. It allows continued monitoring of the benefit/risk
balance of the medicinal product. Healthcare professionals are asked to report
any suspected adverse reactions via the Yellow Card Scheme at
www.mhra.gov.uk/yellowcard.

4.9

Overdose
Symptoms of overdosage include irritability, restlessness, palpitations, hypertension,
difficulty in micturition, nausea, vomiting, thirst and convulsions. In severe
overdosage gastric lavage and aspiration should be performed. Symptomatic and
supportive measures should be undertaken, particularly with regard to cardiovascular
and respiratory systems. Convulsions should be controlled with intravenous
diazepam. Chlorpromazine may be used to control marked excitement and
hallucinations. Severe hypertension may need to be treated with an alphaadrenoreceptor blocking drug, such as phentolamine. A beta blocker may be required
to control cardiac arrhythmias.

5

PHARMACOLOGICAL PROPERTIES

5.1

Pharmacodynamic properties
Phenylephrine is a sympathomimetic agent with mainly direct effects on adrenergic
receptors. It has predominantly alpha adrenergic activity and is without stimulating
effects on the central nervous system. The sympathomimetic effect of phenylephrine
produces vasoconstriction which in turn relieves nasal congestion.

5.2

Pharmacokinetic properties
Phenylephrine is readily absorbed after oral administration but is subject to extensive
presystemic metabolism, much of which occurs in the enterocytes. As a consequence,
systemic bioavailability is only about 40%. Following oral administration, peak
plasma concentrations are achieved in 1-2 hours. The mean plasma half life is in the
range 2-3 hours. Penetration into the brain appears to be minimal.
Following absorption, the drug is extensively metabolised in the liver. Both
phenylephrine and its metabolites are excreted in the urine.
The volume of distribution is between 200 and 500 litres, but there are no data on the
extent of plasma protein binding.

5.3

Preclinical safety data
There are no preclinical data of relevance to the prescriber which are additional to
that already included in other sections of the SPC.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Pregelatinised maize starch
Dried maize starch
Lactose monohydrate
Magnesium stearate
Hard Gelatin Capsule (Gelatin, Quinoline Yellow E104, Titanium dioxide E171)
Ink (Black Iron Oxide E172, Shellac, Propylene glycol)

6.2

Incompatibilities
Not applicable.

6.3

Shelf life
36 months

6.4

Special precautions for storage
Do not store above 25°C. Store in the original package.

6.5

Nature and contents of container
Blister pack of pigmented 250 micron PVC coated with 40gsm PVDC and 20 micron
aluminium foil.
Pack sizes: 5, 6, 7, 10, 12, 14, 18, 20, 21, 24, 25, 28, 30, 36, 48, 50.

6.6

Special precautions for disposal
Not applicable.

7

MARKETING AUTHORISATION HOLDER
The Boots Company PLC
1 Thane Road West
Nottingham
NG2 3AA
United Kingdom

8

MARKETING AUTHORISATION NUMBER(S)
PL 00014/0593

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
13/09/2005

10

DATE OF REVISION OF THE TEXT
23 March 2015

Expand Transcript

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide